C.A.A. Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
C.A.A. Silva has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- A.P.M. Santana
Departamento de Fisiologia e Famacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, Brasil
1 shared publication C.D.H. Lopes
Departamento de Fisiologia e Famacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, Brasil
1 shared publication- C.R.N. Barbosa
Departamento de Fisiologia e Famacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, Brasil
1 shared publication - Deysi Viviana Tenazoa Wong
Postgraduate Program in Pharmacology, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil
1 shared publication - Gerly Anne Castro Brito
Department of Physiology and Pharmacology, Faculty of Medicine Federal University of Ceará Fortaleza Ceará Brazil
1 shared publication - L.L. Carvalho
Departamento de Fisiologia e Famacologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, Brasil
1 shared publication
Latest Publications
- Open Access
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 52 (3) , e8251
Amifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
Oral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) and radiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable. Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy and chemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model of OM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the right cheek pouch; 5-FU (60 and 40 mg/kg, ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg) + 5-FU + scratches. Salivation rate was assessed and the animals were euthanized on day 10 for the analysis of macroscopic and microscopic injury by scores. Tissue samples were harvested for the measurement of neutrophil infiltration and detection of inflammatory markers by ELISA and immunohistochemistry. 5-FU induced pronounced hyposalivation, which was prevented by amifostine (Pvs 5-FU group). Amifostine reduced inflammation and protected against 5-FU-associated oral mucositis and hyposalivation.
- 1 January 2019
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 52 (3) , e8251
Open AccessAmifostine reduces inflammation and protects against 5-fluorouracil-induced oral mucositis and hyposalivation
Oral mucositis (OM) is a common and dose-limiting side effect of cancer treatment, including 5-fluorouracil (5-FU) and radiotherapy. The efficacy of the therapeutic measures to prevent OM is limited and disease prevention is not fully observable. Amifostine is a cytoprotective agent with a described anti-inflammatory potential. It is clinically used to reduce radiotherapy and chemotherapy-associated xerostomia. This study investigated the protective effect of amifostine on an experimental model of OM. Hamsters were divided into six groups: saline control group (5 mL/kg), mechanical trauma (scratches) of the right cheek pouch; 5-FU (60 and 40 mg/kg, ip, respectively, administered on days 1 and 2); amifostine (12.5, 25, or 50 mg/kg) + 5-FU + scratches. Salivation rate was assessed and the animals were euthanized on day 10 for the analysis of macroscopic and microscopic injury by scores. Tissue samples were harvested for the measurement of neutrophil infiltration and detection of inflammatory markers by ELISA and immunohistochemistry. 5-FU induced pronounced hyposalivation, which was prevented by amifostine (Pvs 5-FU group). Amifostine reduced inflammation and protected against 5-FU-associated oral mucositis and hyposalivation.